Actionable news
All posts from Actionable news

Celator Reports on Previously Suspended Investigator-Initiated Clinical Study

EWING, N.J., April 18, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (CPXX) reports that an investigator-initiated clinical study at a university was reported as suspended on The study had previously been suspended due to institutional resource considerations at the university, unrelated to VYXEOS™ (CPX-351). The study is a phase 2 study of VYXEOS for the treatment of acute myeloid leukemia or higher risk myelodysplastic syndrome patients, who relapsed, or were refractory to, prior therapy with hypomethylating agents. Celator understands that the study has since been re-opened.

"To eliminate any confusion, we want to inform investors, the medical community and study participants of these circumstances," said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the...